BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3

BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3

Abstract Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunotherapy has radically changed patients’ outcomes. However, several issues are emerging and their implementation is required to optimize immunotherapy-based protocols. In this wo...

Full description

Bibliographic Details
Main Authors: Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, Elisabetta Sauta, Federica Torricelli, Veronica Manicardi, Eleonora Zanetti, Stefania Orecchioni, Paolo Falvo, Simonetta Piana, Filippo Lococo, Massimiliano Paci, Francesco Bertolini, Alessia Ciarrocchi, Valentina Sancisi
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-46778-8

Internet

https://doi.org/10.1038/s41467-024-46778-8

Similar Items